Insulet (NASDAQ:PODD) Shares Down 5.2% – Here’s What Happened

Insulet Corporation (NASDAQ:PODD)’s share price dropped 5.2% during mid-day trading on Monday . The company traded as low as $158.01 and last traded at $155.8650. Approximately 61,738 shares were traded during mid-day trading, a decline of 95% from the average daily volume of 1,243,904 shares. The stock had previously closed at $164.48.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Zacks said Insulet has a strong earnings surprise history and may be positioned to top quarterly estimates again, which supports the bull case for the stock. Why Insulet (PODD) Could Beat Earnings Estimates Again
• Positive Sentiment: Insulet’s launch of Omnipod 5 and Omnipod Discover in Spain signals continued international expansion for its tubeless diabetes technology, which could support revenue growth. Insulet launches Omnipod 5, Omnipod Discover in Spain
• Positive Sentiment: Deutsche Bank initiated coverage on Insulet with a Buy rating and a $190 price target, reflecting ongoing analyst confidence in the company’s growth prospects. Insulet (PODD): Deutsche Bank Initiates Coverage With a Buy and a $190 Target
• Neutral Sentiment: Several law firms announced or promoted a securities class action tied to Insulet, but these appear to be follow-on litigation updates rather than new company-operating developments. Pomerantz Law Firm Announces the Filing of a Class Action Against Insulet Corporation and Certain Officers – PODD
• Negative Sentiment: The FDA classified a recall of certain Omnipod insulin pods as a Class I recall after injury reports, raising safety concerns and increasing legal and reputational risk. FDA Classifies Insulet Omnipod Recall as Serious After Injury Reports
• Negative Sentiment: Multiple securities-fraud class action filings allege Insulet made misleading statements about manufacturing controls and safety, which adds uncertainty and could weigh on the shares. PODD INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Insulet Corporation Investors

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. UBS Group set a $219.00 price objective on shares of Insulet in a research report on Thursday, June 11th. Sanford C. Bernstein dropped their price objective on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Wells Fargo & Company cut their price objective on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Citigroup reduced their target price on shares of Insulet from $175.00 to $165.00 and set a “neutral” rating for the company in a research note on Thursday, May 28th. Finally, BTIG Research decreased their target price on shares of Insulet from $260.00 to $235.00 and set a “buy” rating for the company in a research report on Tuesday, May 26th. Twenty-two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $237.83.

Insulet Price Performance

The business has a fifty day moving average price of $154.02 and a 200 day moving average price of $213.57. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The company has a market capitalization of $11.19 billion, a price-to-earnings ratio of 37.57, a price-to-earnings-growth ratio of 1.11 and a beta of 1.11.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. During the same quarter in the prior year, the company posted $1.02 earnings per share. The company’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, research analysts expect that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Insider Transactions at Insulet

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the purchase, the director owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.36% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Trust Asset Management LLC bought a new stake in Insulet in the second quarter worth about $119,000. Avior Wealth Management LLC acquired a new stake in Insulet in the 2nd quarter valued at about $265,000. CX Institutional raised its holdings in shares of Insulet by 149.9% in the 2nd quarter. CX Institutional now owns 2,132 shares of the medical instruments supplier’s stock worth $325,000 after purchasing an additional 1,279 shares in the last quarter. Basecamp Wealth Advisors LLC increased its holdings in shares of Insulet by 48.3% in the first quarter. Basecamp Wealth Advisors LLC now owns 313 shares of the medical instruments supplier’s stock valued at $66,000 after buying an additional 102 shares in the last quarter. Finally, Empowered Funds LLC lifted its position in shares of Insulet by 38.1% during the 1st quarter. Empowered Funds LLC now owns 2,880 shares of the medical instruments supplier’s stock valued at $604,000 after acquiring an additional 795 shares during the last quarter.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.